MedTrace Logo

Doxycycline in Acute Traumatic Brain Injury

NCT04239755 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-02-18

No results posted yet for this study

Summary

evaluate the impact of Doxycycline on both clinical outcome and blood levels of NSE in patients with TBI.

Conditions

Interventions

DRUG

Doxycycline 100 MG Oral Tablet

doxycycline 100 mg twice daily, either orally or through a nasogastric tube for 5 day

OTHER

placebo

placebo in addition to the standard treatment.

Sponsors & Collaborators

  • Tanta University

    collaborator OTHER

  • Damanhour University

    lead OTHER

Principal Investigators

  • Noha Mansour, Lecturer · Mansoura University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2020-07-30
Completion
2020-10-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04239755 on ClinicalTrials.gov